Live Report · Updated February 9, 2026

Amgen vs Gilead Sciences

Explore a detailed comparison between Amgen Inc. and Gilead Sciences Inc., examining their distinct business models, financial performance, and relevant market context. This page provides an accessible overview for those seeking to understand key differences and similarities between these two prominent biotechnology companies. Educational content, not financial advice.

Explore a detailed comparison between Amgen Inc. and Gilead Sciences Inc., examining their distinct business models, financial performance, and relevant market context. This page provides an accessibl...

Comparison Snapshot

Key Financial Metrics

AMGN

Metric

GILD

$202.37B

Market Cap

$188.19B

-9.12%

Potential Profit

-5.56%

Buy

Analyst Rating

Buy

Why It's Moving

AMGN Stock Warning: Analysts Flag -9% Downside Amid Breakout Highs and Earnings Jitters

Bernstein downgraded to Market Perform, warning 2026 could stall as obesity drug MariTide awaits Phase 3 data and Repatha battles Merck's new oral rival Enlicitide.
Stock surged 13.7% in three months to hit highs, backed by ~10% revenue growth and low 15.6x forward P/E, drawing target lifts from RBC to $360 and Goldman to $415.
Q4 earnings due Feb 10 expect $9.47B revenue (up 4.3% YoY) and $4.75 EPS despite YOY dip; Amgen's track record of beats tempers downside fears in biotech sector.

Sentiment:

🌋Volatile

GILD Faces Analyst Warnings of 9% Downside Ahead of Pivotal Q4 Earnings Reveal

Implied volatility spikes in Feb. 2026 $150 put options, reflecting trader expectations of significant downside moves and heightened uncertainty.
Q4 earnings due February 10 with consensus at $1.90 per share, up from $1.85 over the last 60 days, putting pressure on Gilead to deliver amid HIV and oncology focus.
Analyst price targets cluster below recent highs around $152, implying roughly 9% risk to the downside despite mostly Buy ratings from major firms.

Sentiment:

🐻Bearish

AMGN Stock Warning: Analysts Flag -9% Downside Amid Breakout Highs and Earnings Jitters

Bernstein downgraded to Market Perform, warning 2026 could stall as obesity drug MariTide awaits Phase 3 data and Repatha battles Merck's new oral rival Enlicitide.
Stock surged 13.7% in three months to hit highs, backed by ~10% revenue growth and low 15.6x forward P/E, drawing target lifts from RBC to $360 and Goldman to $415.
Q4 earnings due Feb 10 expect $9.47B revenue (up 4.3% YoY) and $4.75 EPS despite YOY dip; Amgen's track record of beats tempers downside fears in biotech sector.

Sentiment:

🌋Volatile

GILD Faces Analyst Warnings of 9% Downside Ahead of Pivotal Q4 Earnings Reveal

Implied volatility spikes in Feb. 2026 $150 put options, reflecting trader expectations of significant downside moves and heightened uncertainty.
Q4 earnings due February 10 with consensus at $1.90 per share, up from $1.85 over the last 60 days, putting pressure on Gilead to deliver amid HIV and oncology focus.
Analyst price targets cluster below recent highs around $152, implying roughly 9% risk to the downside despite mostly Buy ratings from major firms.

Sentiment:

🐻Bearish

Investment Analysis

Amgen

AMGN

Pros

Amgen maintains a robust oncology portfolio with blockbuster drugs like Lumakras driving consistent revenue growth.
Rare disease franchise, including Tepezza, provides high-margin recurring revenues and shields against generic erosion.
Strong balance sheet supports dividend growth and strategic acquisitions amid pipeline advancements.

Considerations

Biosimilar competition erodes sales of key blockbusters such as Enbrel and Prolia.
High R&D expenses pressure margins despite obesity drug progress in early stages.
Regulatory delays in novel assets like MariTide expose pipeline execution risks.

Gilead Sciences

GILD

Pros

Dominant HIV franchise with Yeztugo launch momentum bolsters market share alongside Descovy's 45% penetration.
Attractive valuation at forward P/E of 14.19 trades at discount to industry peers.
Expanding oncology pipeline nears key regulatory milestones for sustained growth.

Considerations

Upcoming quarterly EPS projected to decline 1.58% year-over-year amid flat revenue.
Recent insider sales signal potential short-term concerns over performance.
Modest consensus price target implies limited near-term upside from current levels.

Related Market Insights

The Biotech Revolution: Why These Medical Pioneers Could Transform Your Portfolio

Explore the biotech revolution driven by CRISPR & regulatory support. Invest in leaders like Amgen, Gilead, Biogen. Discover high-growth medical pioneers.